Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04335084 · ClinicalTrials.gov registry record · Phase 2
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
A Phase 2 study, sponsored by ProgenaBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT04335084: Completed Phase 2 study, sponsored by ProgenaBiome.
NCT04335084 is a Phase 2 study that has completed, run by ProgenaBiome. The registered enrollment target is 254 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04335084, a Phase 2 study, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
Primary Outcome
Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Hydroxychloroquine
- DIETARY_SUPPLEMENT Vitamin C
- DIETARY_SUPPLEMENT Zinc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 2 |
What the finished NCT04335084 record still lists
NCT04335084 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher).
The record links to 0 conditions, and to 4 interventions - of which Vitamin D is the first listed.
NCT04335084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04335084 about?
NCT04335084 is a clinical study titled "A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection". This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
What is the current status of trial NCT04335084?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2020-06-22. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT04335084?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Hydroxychloroquine (DRUG), Vitamin C (DIETARY_SUPPLEMENT), Zinc (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04335084?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04335084's enrollment target sits among peer trials
254 219th of 2000 higher than 1,781 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI